<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755946</url>
  </required_header>
  <id_info>
    <org_study_id>Roflumilast in DN</org_study_id>
    <nct_id>NCT04755946</nct_id>
  </id_info>
  <brief_title>Possible Role of Roflumilast in Diabetic Nephropathy</brief_title>
  <official_title>Clinical Study Evaluating the Possible Efficacy and Safety of Roflumilast in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      adding roflumilast to the standard therapy for diabetic nephropathy and studying the&#xD;
      progression of many outcomes including urinary albumin to creatinine ratio, estimated GFR,&#xD;
      biomarkers of diabetic nephropathy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2021</start_date>
  <completion_date type="Anticipated">July 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in urinary albumin creatinine ratio (UACR)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>measuring UACR pre and post experiment and substracting and dividing on baseline level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>substracting pre-treatment from post-treatment values of EGFR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary pro-inflammatory cytokine MCP-1</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>substracting pre-treatment from post-treatment values of Change in Urinary pro-inflammatory cytokine MCP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum irisin level</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>substracting pre-treatment from post-treatment values of serum irisin level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>roflumilast arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management</description>
    <arm_group_label>roflumilast arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: diabetic patients with persistent micro- or macroalbuminuria despite&#xD;
        treatment with the maximum tolerated dose of ACE inhibitors for at least 8 weeks before the&#xD;
        screening and randomization&#xD;
&#xD;
          -  Type I or II diabetic patient with stage 2 CKD (eGFR = 60 - 89 ml/min) ,stage 3 CKD&#xD;
             (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  moderate to severe hepatic disease (Child-Pugh B or C) severe renal disease (eGFR&lt;15&#xD;
             ml/min) body-mass index below 25 kg/m2 concomitant use of strong cytochrome P450&#xD;
             inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin) known psychiatric&#xD;
             illness, congestive heart disease patients with allergy for roflumilast pregnant and&#xD;
             lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham M Elnahhas, Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharm D</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hisham M Elnahhas, Pharm D</last_name>
    <phone>01020515956</phone>
    <phone_ext>002</phone_ext>
    <email>PG_76772@pharm.tanta.edu.eg</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Hisham Mohammad Abd-El-Galil El-Nahhas</investigator_full_name>
    <investigator_title>Pharm D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data of outcomes and other research but not personal data are intended to be published in application to scientific journals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

